top of page

IDMIT Team Highlights New Advances in Imaging and Collaborations

  • Photo du rédacteur: Maïa Klzn
    Maïa Klzn
  • 1 sept. 2024
  • 1 min de lecture

The team led by Roger Legrand at IDMIT is pleased to share two key developments that mark significant progress in our research and strategic positioning within major national programs.


-       In Vivo Imaging of CD8+ T Cells: Proof of Concept for TiiLT Technologies

The recent publication by De Groof et al., focusing on the in vivo imaging of CD8+ T cells, showcases a promising advancement in immunological imaging. Although this study was not formally funded by the TiiLT program, it provides a crucial proof of concept for the application of this technology within our programme.


  - Official Launch of IHU “Prometheus” on Sepsis — A France 2030 Initiative

IDMIT is also proud to announce the official launch of the University Hospital Institute (IHU) “Prometheus,” a groundbreaking initiative focused on tackling sepsis, where IDMIT serves as co-coordinator. This France 2030 flagship program represents the world’s first integrated center combining research, clinical care, and training dedicated to overcoming sepsis.


Importantly, this new initiative could open valuable opportunities for the development and application of TiilT molecules within the context of inflammatory and infectious diseases.

Learn more about IHU Prometheus:

·       AP-HP Press Release

·       CEA Press Release

 
 
 

Posts récents

Voir tout
The IVORY Study

The IVORY study, conducted with the involvement of Ziad Mallat from Inserm, explored the therapeutic potential of low-dose interleukin-2 to reduce arterial inflammation in patients with acute coronary

 
 
 

Commentaires


bottom of page